IMATINIB MESYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H31N7O.CH4O3S
Molecular Weight	589.708
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CC=CN=C5)=C(C)C=C3)CC1

InChI

InChIKey=YLMAHDNUQAMNNX-UHFFFAOYSA-N

InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C29H31N7O
Molecular Weight	493.6027
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009892

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Bcr/Abl fusion protein 16 Target ID: CHEMBL2096618 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Inhibitor 8228	0.025 µM [IC50]
Platelet-derived growth factor receptor alpha 30 Target ID: CHEMBL2007 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Inhibitor 8228	0.1 µM [IC50]
Stem cell growth factor receptor 52 Target ID: CHEMBL1936 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Inhibitor 8228	0.1 µM [IC50]
Platelet-derived growth factor receptor beta 55 Target ID: CHEMBL1913 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Inhibitor 8228	39.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Philadelphia chromosome positive chronic myeloid leukemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Primary	Approved 8360	GLEEVEC Approved Use Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. Launch Date 9.8945283E11
Philadelphia chromosome positive acute lymphoblastic leukemia 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Primary	Approved 8360	GLEEVEC Approved Use Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. Launch Date 9.8945283E11
Myelodysplastic/myeloproliferative diseases associated with PDGFR 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Primary	Approved 8360	GLEEVEC Approved Use Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. Launch Date 9.8945283E11
Aggressive systemic mastocytosis (D816V c-Kit mutation status negative/c-Kit mutational status unknown) 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Primary	Approved 8360	GLEEVEC Approved Use Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. Launch Date 9.8945283E11
Hypereosinophilic syndrome 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf	Primary	Approved 8360	GLEEVEC Approved Use Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST. Launch Date 9.8945283E11

C_max

Value	Dose	Analyte	Population
1.74 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15796158	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4478 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1907.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3508.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1907.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16122278	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.82 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.75 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.71 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
19.9 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15796158	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
174.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
89.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.8 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16122278	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
63.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
97.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
15.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15796158	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18359865	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CGP-74588 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14990650	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16122278	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	IMATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 2 times / day steady, oral MTD Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
400 mg 2 times / day steady, oral Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	DLT: Transaminases increased... Dose limiting toxicities: Transaminases increased (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	DLT: Neutropenia, Hypocalcemia... Dose limiting toxicities: Neutropenia (grade 3, 2 patients) Hypocalcemia (grade 4, 2 patients) Hypophosphatemia (grade 4, 2 patients) Hypokalemia (grade 3, 2 patients) Nausea (grade 3, 2 patients) Emesis (grade 3, 2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18359865

AEs

AE	Significance	Dose	Population
Transaminases increased	grade 3, 1 patient DLT	400 mg 2 times / day steady, oral Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Emesis	grade 3, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Hypokalemia	grade 3, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Nausea	grade 3, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Neutropenia	grade 3, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Hypocalcemia	grade 4, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865
Hypophosphatemia	grade 4, 2 patients DLT	600 mg 2 times / day steady, oral Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18359865	unhealthy, 53.3 years (range: 29.8–69.9 years) n = 35 Health Status: unhealthy Condition: malignant glioma Age Group: 53.3 years (range: 29.8–69.9 years) Sex: M+F Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/18359865

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709	substrate 1010 inhibitor 1752	substrate 1193 inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A4/5 273 CYP1A2 1509 CYP2A6 704 CYP2C19 1463 CYP2B6 799 CYP2E1 876 CYP4A9/11 37	CYP3A5 391 CYP1A2 1032 CYP2C8 688 CYP2C19 985

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2B6 985	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	no
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	no
CYP4A9/11 37	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [IC50 120 uM]
CYP2A6 736	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [IC50 230 uM]
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [IC50 410 uM]
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [Ki 27 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [Ki 7.5 uM]
CYP3A4/5 330	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	yes [Ki 8 uM]	yes (co-administration study) Comment: imatinib increased cmax of simvastatin by 2x, auc by 3.5x Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	major	yes (co-administration study) Comment: ketoconazole increased cmax of imatinib by 26%, auc by 40% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor
CYP2C8 688	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor
CYP3A5 391	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_biopharmr_P1.pdf	minor

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/23196655/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45783	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45783
ChemicalBook	CB7370890	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7370890
MolPort	MolPort-000-883-342	https://www.molport.com/shop/molecule-link/MolPort-000-883-342
Selleck Chemicals	Imatinib(STI571)	http://www.selleckchem.com/products/Imatinib(STI571).html
ZINC	ZINC000019632618	http://zinc15.docking.org/substances/ZINC000019632618
eMolecules	876446	https://www.emolecules.com/cgi-bin/more?vid=876446

PubMed

Title	Date	PubMed
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.	2001	11549802
Sarcoma.	2001	11524551
The oncologic four-minute mile.	2001	11423668
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.	2001 Apr 1	11264164
ARG tyrosine kinase activity is inhibited by STI571.	2001 Apr 15	11290609
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.	2001 Apr 5	11287980
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.	2001 Apr 5	11287975
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.	2001 Aug 16	11526490
[New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor].	2001 Aug 27	11572056
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.	2001 Aug 3	11423618
Bcr-Abl inhibition as a modality of CML therapeutics.	2001 Aug 31	11553417
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.	2001 Feb	11512148
The biology and treatment of chronic myelogenous leukemia.	2001 Jan	11271979
Implications of imatinib mesylate for hematopoietic stem cell transplantation.	2001 Jul	11526599
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition.	2001 Jul	11526598
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.	2001 Jul	11526597
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.	2001 Jul	11526596
The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.	2001 Jul	11526595
Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.	2001 Jul	11526594
Cancer treatment. New drugs, new hope.	2001 Jul	11511447
Clinical trials referral resource. ST1571.	2001 Jul	11499689
[STI571 and gastro intestinal stromal tumors].	2001 Jul	11495818
[Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].	2001 Jul	11495817
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].	2001 Jul	11495816
New leukemia drug receives FDA approval.	2001 Jul	11433951
Approval heralds new generation of kinase inhibitors?	2001 Jul	11433254
New-age drug meets resistance.	2001 Jul 19	11460142
STI571 revolution: can the newer targeted drugs measure up?	2001 Jul 4	11438556
From the Food and Drug Administration.	2001 Jul 4	11434814
Current treatment approaches for chronic myelogenous leukemia.	2001 Jul-Aug	11504279
Gastrointestinal stromal tumor workshop.	2001 Jun	11431711
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.	2001 Jun	11417489
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.	2001 Mar	11298594
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.	2001 Mar	11290430
Novel therapies for chronic myelogenous leukemia.	2001 May	11376866
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.	2001 May	11368438
STI571: a gene product-targeted therapy for leukemia.	2001 May	11296132
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.	2001 May 1	11291071
In search of the silver bullet.	2001 May 14	11379577
Cancer's mechanics. Targeting errant cells.	2001 May 21	11383095
New hope for cancer.	2001 May 28	11393038
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.	2001 Nov	11597734
Improving the management of chronic myeloid leukaemia.	2001 Sep	11584615
A possible role for STI571 in the treatment of idiopathic myelofibrosis.	2001 Sep	11559942
Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571.	2001 Sep	11532632
Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.	2001 Sep	11532349
Cancer in the crosshairs.	2001 Sep	11524965
Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.	2001 Sep 1	11520804
Roots of clinical resistance to STI-571 cancer therapy.	2001 Sep 21	11569495
Small molecule: large hopes.	2001 Sep-Oct	11584898

Patents

Sample Use Guides

In Vivo Use Guide

The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.

Route of Administration: Oral

In Vitro Use Guide

Imatinib (CGP 57148) was tested for growth inhibition of EGF-dependent BALB/MK cells, the H-ras-transformed T24 bladder carcinoma line, and IL-3-dependent growth of FDC-Pl cells. The compound showed only weak antiproliferative activity against these cell lines, with IC50 values of 12.7 uM, 9.4 uM, and 29.2 uM, respectively. However, when tested on v-abl-transformed PB-3c cells, incubation with CGP 57148 resulted in potent growth inhibition even in the presence of exogenous IL-3 (IC50 values, 0.11 uM without IL-3 and 0.9 uM with IL-3). Similar results were obtained using v-sis-transformed BALB/c 3T3 cells, which grow in response to autocrine PDGF production (IC50, 0.33 uM).

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:17:36 UTC 2023` Edited by `admin` on `Wed Jul 05 23:17:36 UTC 2023`
Record UNII	8A1O1M485B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMATINIB MESYLATE

Official Name

English

IMATINIB MESYLATE [USAN]

Common Name

English

IMATINIB METHANE SULFONATE

Common Name

English

IMATINIB METHANESULFONATE

Common Name

English

IMATINIB ACCORD

Brand Name

English

IMATINIB MESILATE [MART.]

Common Name

English

IMATINIB MESILATE [EP MONOGRAPH]

Common Name

English

QTI571

Code

English

IMATINIB MESILATE

Common Name

English

Imatinib mesilate [WHO-DD]

Common Name

English

IMATINIB MESYLATE [ORANGE BOOK]

Common Name

English

NSC-716051

Code

English

IMATINIB MESYLATE [HSDB]

Common Name

English

GLIVEC

Common Name

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULFONATE SALT

Common Name

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULPHONATE SALT

Common Name

English

IMATINIB MESYLATE [VANDF]

Common Name

English

IMATINIB MESILATE [JAN]

Common Name

English

IMATINIB MEDAC

Brand Name

English

GLEEVEC

Brand Name

English

STI571

Code

English

IMATINIB METHANESULFONATE [MI]

Common Name

English

STI-571

Code

English

STI 571

Code

English

QTI-571

Code

English

IMATINIB (AS MESILATE)

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

209005

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB ACCORD (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB MEDAC (AUTHORIZED: HYPEREOSINOPHILIC SYNDROME)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB ACTAVIS (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

GLIVEC (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

EMA ASSESSMENT REPORTS

GLIVEC (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

FDA ORPHAN DRUG

209205

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

FDA ORPHAN DRUG

149201

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

NCI_THESAURUS

C155700

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB MEDAC (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

GLIVEC (AUTHORIZED: HYPEREOSINOPHILIC SYNDROME)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

EMA ASSESSMENT REPORTS

GLIVEC (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB ACCORD (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB MEDAC (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

FDA ORPHAN DRUG

428914

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB ACCORD (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

FDA ORPHAN DRUG

209105

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB ACCORD (AUTHORIZED:HYPEREOSINOPHILIC SYNDROME)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EU-Orphan Drug

EU/3/01/021

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB TEVA (AUTHORIZED:

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

FDA ORPHAN DRUG

208805

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

FDA ORPHAN DRUG

741420

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

EMA ASSESSMENT REPORTS

IMATINIB MEDAC (AUTHORIZED: LEUKEMIA, MYELOMONOCYTIC, CHRONIC)

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

Code System Code Type Description

HSDB

7142

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

RXCUI

284924

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

RxNorm

EPA CompTox

DTXSID9040502

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

MERCK INDEX

M6213

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

Merck Index

EVMPD

SUB12517MIG

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

DRUG BANK

DBSALT000098

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

PUBCHEM

123596

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

DAILYMED

8A1O1M485B

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

SMS_ID

100000091825

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

USAN

MM-81

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

ChEMBL

CHEMBL941

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

NCI_THESAURUS

C1687

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

CHEBI

45783

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

NSC

716051

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

FDA UNII

8A1O1M485B

Created by admin on Wed Jul 05 23:17:37 UTC 2023 , Edited by admin on Wed Jul 05 23:17:37 UTC 2023

PRIMARY

CHEBI

31690

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

CAS

220127-57-1

Created by admin on Wed Jul 05 23:17:36 UTC 2023 , Edited by admin on Wed Jul 05 23:17:36 UTC 2023

PRIMARY

Related Record Type Details


					BKJ8M8G5HI

IMATINIB

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					6GOH0N63QD

CGP-74588

IMPURITY -> PARENT

Amount:


					JR9RZF7KDS

IMATINIB AMINE

IMPURITY -> PARENT

Amount:


					MD6L0C82BN

(E)-3-DIMETHYLAMINO-1-(PYRIDIN-3-YL)PROP-2-EN-1-ONE

IMPURITY -> PARENT

Amount:

Related Record Type Details


					BKJ8M8G5HI

IMATINIB

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009892

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009892

C_max

T_1/2

F_unbound

Drug as perpetrator